



ASX release

20 April 2009

**US\$0.6 million new pharmaceutical trial contract  
Over US\$7.9 million new contracts in past 11 months**

AtCor Medical Limited (ASX:ACG), the developer and marketer of the SphygmoCor system which measures central blood pressures and arterial stiffness noninvasively, today announced that it has signed a new contract to supply SphygmoCor systems and clinical trial support services to a leading international pharmaceutical company. This contract is with an existing client and has a minimum value of US\$579,000. The contract brings the total value of US pharmaceutical trial contracts secured over the past 11 months to US\$7.9 million.

Duncan Ross, AtCor Medical CEO, said "We are again very pleased to secure additional business with an existing customer. AtCor's strong customer retention in new clinical trials demonstrates the importance of non-invasive central blood pressure data in drug development, as well as the high quality of the services we provide."

**Central blood pressure assessment in clinical trials: vital to understand subject risk and drug effects**

"Scientific literature shows how important it is to measure central blood pressure in clinical trials and in patient care," Ross continued. "The recently published Anglo Cardiff II study showed that many patients with controlled brachial blood pressure may have central pressure equivalent to patients with Stage One Hypertension. Many major independent studies, such as CAFE and Strong Heart, have shown that elevated central pressure is a superior predictor of cardiovascular events and that central blood pressure cannot be determined with brachial blood pressure measurements. So, to understand existing cardiovascular risk in subjects enrolled in trials, and the risks and benefits of drugs in development, central blood pressures must be measured."

**About AtCor Medical**

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring.

More than 1,900 SphygmoCor systems are currently in use worldwide at major medical and research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States and in Europe. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com).

*For further information, please contact:*

*Media enquiries to:*

Duncan Ross – AtCor Medical CEO  
+1 (630) 228 8874

Ashley Rambukwella – Financial &  
Corporate Relations

Peter Manley – AtCor Medical CFO  
+61 (2) 9874 8761

Ph: +61 (2) 8264 1004/ m. 0407 231 282

SphygmoCor® is a registered trademark of AtCor Medical Pty Ltd and its related entities.